Peter Voorhees, MD

home / authors / peter-voorhees-md

Articles

Challenges in Optimizing Sequencing Strategies in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

November 1st 2024

Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.

Unmet Needs and Future Perspectives in Treatment Sequencing Strategies in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

November 1st 2024

The panel concludes its discussion with key takeaways on unmet needs and evolving treatment paradigms in relapsed/refractory multiple myeloma.

Challenges in Optimizing Sequencing

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 25th 2024

Future Clinical Trials: Sequencing Decisions for Bispecifics and CAR T-Cell Therapy

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 25th 2024

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

Treatment Options for Late-line R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 18th 2024

Following the presentation of a case of a patient with relapsed/refractory multiple myeloma, the expert panel reviews treatment options.

Overview of CAR-T Sequencing Strategies in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 18th 2024

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

Consideration in Treatment Selection and Sequencing in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 11th 2024

The panel discusses how they approach treatment selection and sequencing for patients with relapsed/refractory multiple myeloma.

Clinical Scenario 2: A 70-Year-Old Male with R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 11th 2024

Shaji Kumar, MD, presents the case of a 70-year-old patient with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Pooled Analysis from MagnetisMM Studies

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 4th 2024

Thomas G. Martin, MD, reviews findings from a pooled analysis from MagnetisMM that evaluated elranatamab in patients with relapsed/refractory MM who received prior BCMA-directed therapies.

Sequencing Options of Bispecifics in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

September 27th 2024

Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.

Treatment Options in Late-line R/R MM Patients

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

September 20th 2024

Following the presentation of a case of a patient with multiple myeloma, the panel have a roundtable discussion on how to approach treatment.

Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

September 20th 2024

A panel of myeloma specialists review the case of a 67-year-old patient with multiple myeloma (MM) who received a bispecific antibody.

A panel of 4 experts on multiple myeloma seated at a long table

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

October 18th 2023

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

October 18th 2023

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

October 11th 2023

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

October 11th 2023

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

October 4th 2023

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

Talquetamab for Patients With Relapsed/Refractory MM

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

October 4th 2023

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MM

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 27th 2023

Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.

MM: Influence of CAR T-Cell Therapy on Clinical Care

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 27th 2023

The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.

CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 20th 2023

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 20th 2023

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

Assessing Frailty in Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 13th 2023

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

Treatment Strategies for Patients With Transplant-Ineligible MM

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 13th 2023

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

Transplant and Treatment Decision-Making in Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 6th 2023

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Multiple Myeloma: Data on Outcomes Based On Cytogenetics

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

September 6th 2023

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

Treatment Options for Patients With Newly Diagnosed Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

August 30th 2023

A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.

The Role of Transplant in Newly Diagnosed Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

August 30th 2023

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

$Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM$